Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.6 - $2.48 $373,280 - $578,584
233,300 Added 24.19%
1,197,800 $2.96 Million
Q4 2023

Feb 14, 2024

SELL
$1.66 - $2.41 $795,618 - $1.16 Million
-479,288 Reduced 33.2%
964,500 $2.22 Million
Q3 2023

Nov 14, 2023

BUY
$1.55 - $3.31 $607,669 - $1.3 Million
392,045 Added 37.28%
1,443,788 $3.45 Million
Q2 2023

Aug 14, 2023

SELL
$1.52 - $2.78 $389,510 - $712,394
-256,257 Reduced 19.59%
1,051,743 $1.64 Million
Q1 2023

May 15, 2023

SELL
$2.36 - $3.35 $1.32 Million - $1.87 Million
-558,274 Reduced 29.91%
1,308,000 $3.31 Million
Q4 2022

Feb 14, 2023

SELL
$2.58 - $4.68 $1.55 Million - $2.82 Million
-601,885 Reduced 24.39%
1,866,274 $5.02 Million
Q3 2022

Nov 14, 2022

BUY
$2.7 - $4.3 $93,690 - $149,210
34,700 Added 1.43%
2,468,159 $6.79 Million

Others Institutions Holding TLRY

About Tilray Brands, Inc.


  • Ticker TLRY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 611,401,984
  • Market Cap $1.01B
  • Description
  • Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Welln...
More about TLRY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.